APP (C99 Fragment) (C-Term) Polyclonal Antibody

Amyloid precursor protein (APP) is a type I transmembrane protein that has a central role in the pathogenesis of Alzheimer’s disease, as well as additional roles in brain development, neuronal plasticity, and memory.{59228} APP is cleaved by ?-secretase (BACE) in neuronal endosomes during amyloidogenic processing of APP, generating the C-terminal C99 fragment, which is localized to the endoplasmic membrane.{59223,59224} C99 is further cleaved by ?-secretase, liberating the APP intracellular domain (AICD) and generating amyloid-? (A?) peptides of various lengths, including A?40 (Item No. 21617) and A?42 (Item No. 20574), which are hallmarks of Alzheimer's disease. APP can also be cleaved by ?-secretase during non-amyloidogenic processing of APP, which occurs at the neuronal plasma membrane and generates the neuroprotective soluble APP fragment sAPP?, as well as a variety of other fragments, including the C47 fragment.{59228,59226} Transgenic mice expressing mutant forms of APP exhibit extracellular A? deposits in the brain, as well as cognitive dysfunction, and are widely used models of Alzheimer’s disease.{59227} Intraneuronal C99 levels are increased in the transgenic APPE693Q mouse model of Alzheimer’s disease, as well as postmortem frontal cortex from patients with sporadic Alzheimer's disease.{59224,59225} Cayman's APP (C99 Fragment) (C-Term) Polyclonal Antibody can be used for ELISA and Western blot (WB) applications. The antibody recognizes the C-terminal region corresponding to the C99 fragment to detect intact APP, as well as the C47 APP fragment, at 18 kDa and 9 kDa, respectively, from human samples.